Huperzine A for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials.
DOI: 10.1371/journal.pone.0074916
archive: archived pipeline: cataloged verified
Get this paper ↗ (DOI — opens at the source; we link to it, we don't host it)
Summary
This systematic review and meta-analysis evaluates the efficacy and safety of Huperzine A, a Chinese herbal extract and acetylcholinesterase inhibitor, for the treatment of Alzheimer’s disease (AD). Motivated by the urgent need for effective AD treatments and previous inconclusive evidence due to small sample sizes and poor methodological quality in earlier reviews, the authors aimed to provide a comprehensive assessment of Huperzine A’s beneficial and harmful effects. The researchers searched PubMed, the Cochrane Library, and four major Chinese electronic databases from inception to June 2013 for randomized clinical trials (RCTs). They included 20 RCTs involving 1,823 participants, with treatment durations ranging from 8 to 36 weeks and doses averaging 0.37 mg daily. Comparisons included Huperzine A versus placebo, no treatment, psychotherapy, conventional medicine, and Chinese herbal medicine alone. Data were synthesized using RevMan 5.1 software, employing fixed-effect models unless heterogeneity was present. Methodological quality was assessed using the Cochrane risk of bias tool. The results indicated that Huperzine A significantly improved cognitive function compared to placebo, as measured by the Mini-Mental State Examination (MMSE) at 8, 12, and 16 weeks, and by the Hachinski Dementia Scale (HDS) and Wechsler Memory Scale (WMS) at 8 and 12 weeks. Activities of daily living (ADL) also favored Huperzine A at 6, 12, and 16 weeks. One trial demonstrated improved global clinical assessment via the Clinical Dementia Rating Scale (CDR). Comparisons with no treatment, psychotherapy, and conventional medicine yielded similar favorable findings, though some trials showed no statistical difference when compared to galantamine or donepezil. No trials reported quality of life outcomes. Regarding safety, no severe adverse events were reported; mild side effects included nausea, anorexia, and dizziness, with no significant difference in incidence between groups. The authors conclude that Huperzine A appears to have beneficial effects on cognitive function, daily living activities, and global clinical assessment in AD patients. However, they caution that these findings must be interpreted with care due to the high risk of bias in most included trials. Issues such as inadequate reporting of randomization, allocation concealment, and blinding, along with potential publication bias indicated by asymmetrical funnel plots, limit the certainty of the evidence. The review highlights the need for more rigorous, well-reported RCTs to firmly establish the clinical utility of Huperzine A.
Provenance
The full processing record for this entry. Every stage of this paper's journey through the pipeline is logged — what ran, with which tool and model, how many attempts it took, and when it last completed.
| Stage | Outcome | Tool | Model | Prompt | Attempts | Completed |
|---|---|---|---|---|---|---|
| discover | success | DOAJ | — | — | 1 | 2026-06-18 |
| archive | success | unpaywall | — | — | 1 | 2026-06-25 |
| extract | success | cached | — | — | 2 | 2026-06-26 |
| clean | success | clean | — | — | 1 | 2026-06-18 |
| chunk | success | chunk | — | — | 1 | 2026-06-18 |
| embed | success | embed | Qwen/Qwen3-Embedding-8B | — | 1 | 2026-06-18 |
| promote | success | — | — | — | 1 | 2026-06-18 |
| summarize | success | llm | qwen3.6-27b-prismaquant | summ-v5 | 1 | 2026-06-26 |
| tag | success | vector_similarity | — | — | 6 | 2026-06-18 |
| verify | success | — | — | — | 1 | 2026-06-26 |
Summary generated by qwen3.6-27b-prismaquant on 2026-06-26; verification: verified.
Topics
Ranked by relevance to this paper. Hover a topic for its definition.